Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Income from Continuing Operations (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Income from Continuing Operations for 4 consecutive years, with 11146000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 52.69% to 11146000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 35466000.0, a 33.13% increase, with the full-year FY2025 number at 35466000.0, up 33.13% from a year prior.
  • Income from Continuing Operations was 11146000.0 for Q4 2025 at Spruce Biosciences, down from 8212000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2067000.0 in Q2 2025 to a low of 23559000.0 in Q4 2024.
  • A 4-year average of 11412500.0 and a median of 11513000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 136.77% in 2024, then surged 77.49% in 2025.
  • Spruce Biosciences' Income from Continuing Operations stood at 11144000.0 in 2022, then rose by 10.71% to 9950000.0 in 2023, then tumbled by 136.77% to 23559000.0 in 2024, then surged by 52.69% to 11146000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Income from Continuing Operations are 11146000.0 (Q4 2025), 8212000.0 (Q3 2025), and 2067000.0 (Q2 2025).